24872 Federal Register / Vol. 60, No. 90 / Wednesday, May 10, 1995 / Notices

Contact Person: Phyllis D. Artis, Grant

Technical Assistant, Parklawn Building,

Room 9C–26, 5600 Fishers Lane, Rockville,

MD 20857, Telephone: 301, 443–6470.

The meetings will be closed in

accordance with the provisions set forth

in sec. 552b(c)(4) and 552b(c)(6), Title 5,

U.S.C. Applications and/or proposals

and the discussions could reveal

confidential trade secrets or commercial

property such as patentable material

and personal information concerning

individuals associated with the

applications and/or proposals, the

disclosure of which would constitute

clearly unwarranted invasion of

personal privacy.

(Catalog of Federal Domestic Assistance

Program Numbers 93.126, Small Business

Innovation Research; 93.176, ADAMHA

Small Instrumentation Program Grants;

93.242, Mental Health Research Grants;

93.281, Mental Research Scientist

Development Award and Research Scientist

Development Award for Clinicians; 93.282,

Mental Health Research Service Awards for

Research Training; and 93.921, ADAMHA

Science Education Partnership Award.)

Dated: May 3, 1995.

Susan K. Feldman,

Committee Management Officer, NIH.

[FR Doc. 95–11420 Filed 5–9–95; 8:45 am]

BILLING CODE 4140–01–M

Prospective Grant of Exclusive

License: Oncoimmunins

AGENCY: National Institutes of Health,

Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: This notice in accordance

with 35 U.S.C. 209(c)(1) and 37 CFR

404.7(a)(1)(I) that the National Institutes

of Health and Human Services, is

contemplating the grant of an exclusive

world-wide license to practice the

inventions embodied in a U.S. Patent

5,364,619 and U.S. Patent Applications;

USSN 07/764,695 and USSN 08/218,023

and corresponding foreign patent

applications each entitled,

‘‘Oncoimmunins’’ to OncoImmunin,

Inc. of Kensington, Maryland. The

patent rights in these inventions have

been assigned to the United States of

America.

The prospective exclusive license will

be royalty-bearing and will comply with

the terms and conditions of 35 U.S.C.

209 and 37 CFR 404.7. The prospective

exclusive license may be granted unless

within sixty (60) days from the date of

this published notice, NIH receives

written evidence and argument that

establishes that the grant of the license

would not be consistent with the

requirements of 35 U.S.C. 209 and 37

CFR 404.7.

Tumor-infiltrating lymphocytes (TILs)

have shown in vivo antitumor efficacy

in both animal and human studies.

Functions thought necessary for

antitumor activity include cytolysis,

homing, and proliferation at tumor sites.

T-cell mitogens of tumor origin have

been suggested to be responsible, in

part, for the local stimulation of Tlymphocytes around tumors. Two

tumor-derived, soluble proteins named

Oncoimmunin-L and Oncoimmunin-M

have been isolated and partially

characterized. Oncoimmunin-L is a Tcell mitogen and Oncoimmunin-M is a

myeloid differentiation inducing agent.

The partial characterization of these two

factors has shown that they are similar

to human leukocyte elastase inhibitor

and human lactate dehydrogenase M,

respectively. As cells of both lymphoid

and myeloid origin are known to play

roles in immune defense, factors which

can modulate their number and/or

function may be useful in the diagnosis

and treatment of cancer. Since these

factors are derived from tumors, their

appearance in blood may signal the

presence of tumor or of metastatic

disease. The in vivo bioactivities of

these factors suggests their utility as

therapeutic agents for cancer and

infectious diseases.

ADDRESSES: Requests for copies of the

patent applications, inquiries,

comments and other materials relating

to the contemplated licenses should be

directed to: Raphe Kantor, Ph.D.,

Technology Licensing Specialist, Office

of Technology Transfer, National

Institutes of Health, 6011 Executive

Boulevard, Suite 325, Rockville,

Maryland 20852–3804. Telephone: (301)

496–7735 ext. 247; Facsimile: (301)

402–0220. A signed Confidentiality

Agreement will be required to receive

copies of the patent applications.

Applications for a license in any field of

use filed in response to this notice will

be treated as objections to the grant of

the contemplated licenses. Only written

comments and/or applications for a

license which are received by NIH on or

before July 10, 1995 will be considered.

Dated: April 24, 1995.

Maria C. Freire,

Director, Office of Technology Transfer.

[FR Doc. 95–11423 Filed 5–9–95; 8:45 am]

BILLING CODE 4140–01–P

Prospective Grant of Exclusive

License: Neuro-Derived Fetal Cell

Lines for Transplantation Therapy

AGENCY: National Institutes of Health,

Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: This is notice in accordance

with 35 U.S.C. 209(c)(1) and 37 CFR

404.7(a)(1)(i) that the National Institutes

of Health (NIH), Department of Health

and Human Services, is contemplating

the grant of an exclusive world-wide

license to practice the inventions

embodied in U.S. Patent 4,707,448,

entitled ‘‘Immortal Line of Human Fetal

Glial Cells,’’ U.S. Patent Application SN

08/046,527 entitled ‘‘Use of NeuroDerived Fetal Cell Line for

Transplantation Therapy’’ and

corresponding foreign patent

applications to Pro-Virus, Inc. of

Rockville, Maryland. The patent rights

in these inventions have been assigned

to the United States of America.

The prospective exclusive license will

be royalty-bearing and will comply with

the terms and conditions of 35 U.S.C.

209 and 37 CFR 404.7. The prospective

exclusive license may be granted unless

within 60 days from the date of this

published notice, NIH receives written

evidence and argument that establishes

that the grant of the license would not

be consistent with the requirements of

35 U.S.C. 209 and 37 CFR 404.7.

The patent discloses a novel

immortalized fetal glial cell line,

designated SVG. The pending patent

application discloses the methods of

using such cell lines or genetically

modified clones thereof for therapeutic

purposes to treat various neurological

diseases and disorders via

transplantation of the cell lines into the

patient. Cell lines, such as SVG, have

the advantage of being a continually

renewable resource and relatively

homogenous. Additionally, such cell

lines eliminate the significant safety

concerns associated with primary

human fetal tissue transplants that may

harbor opportunistic disease-causing

agents and may be subjected to a battery

of tests to ensure their safety and

efficacy before being used in

transplantation.

ADDRESSES: Requests for copies of the

patent and the patent applications,

inquiries, comments and other materials

relating to the contemplated licenses

should be directed to: Mr. Arthur J.

Cohn, Esq., Technology Licensing

Specialist, Office of Technology

Transfer, National Institutes of Health,

6011 Executive Boulevard, Suite 325,

Rockville, Maryland 20892–3804.

Telephone: (301) 496–7735 ext 284;

Facsimile: (301) 402–0220. A signed

Confidentiality Agreement will be

required to receive copies of the patent

applications. Applications for a license

in the field of use filed in response to

this notice will be treated as objections

to the grant of the contemplated
Federal Register / Vol. 60, No. 90 / Wednesday, May 10, 1995 / Notices 24873

licenses. Only written comments and/or

applications for a license which are

received by NIH on or before July 10,

1995 will be considered.

Dated: April 26, 1995.

Maria C. Freire,

Director, Office of Technology Transfer.

[FR Doc. 95–11424 Filed 5–9–95; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HOUSING AND

URBAN DEVELOPMENT

[Docket No. N–95–3799; FR–3711–N–03]

Office of the Assistant Secretary for

Public and Indian Housing;

Announcement of Funding Awards for

Technical Assistance to Public

Housing Authorities and Public

Housing Police Departments

AGENCY: Office of the Assistant

Secretary for Public and Indian

Housing.

ACTION: Announcement of funding

awards.

SUMMARY: According to section

102(a)(4)(C) of the Department of

Housing and Urban Development

Reform Act of 1989, this document

notifies the public of the funding award

for Fiscal Year (FY) 1995 Technical

Assistance to Public Housing

Authorities and Public Housing Police

Departments. The purpose of this

document is to announce the name and

address of the award winner and the

amount of the award.

FOR FURTHER INFORMATION CONTACT:

Malcolm E. Main, Crime and Prevention

Division, Office Community Relations

and Involvement, Public and Indian

Housing, Department of Housing and

Urban Development, Room 4116, 451

Seventh Street, SW., Washington, DC.

20410, telephone (202) 708–1197. A

telecommunications device for hearing

or speech impaired persons (TDD) is

available at (202) 708–0850. (These are

not toll-free telephone numbers.)

SUPPLEMENTARY INFORMATION:

I. Authority

This grant is authorized under

Chapter 2, Subtitle C, Title V of the

Anti-Drug Abuse Act of 1988 (42 U.S.C.

11901 et. seq.), as amended by Section

581 of the National Affordable Housing

Act of 1990 (NAHA), approved

November 28, 1990, Pub. L. 101–625,

and Section 161 of the Housing and

Community Development Act of 1992

(HCDA 1992) (Pub. L. 102–550,

approved October 28, 1992).

II. Federal Fiscal Year 1995 Funding

The Departments of Veterans Affairs

and Housing and Urban Development,

and Independent Agencies

Appropriations Act 1995, (approved

September 28, 1994, Pub. Law 103–327),

(95 App. Act) appropriated $290 million

for the Drug Elimination Program. Of

the total $290 million appropriated, $10

million will fund drug elimination

technical assistance, contracts and other

assistance training, program

assessments, and execution for or on

behalf of public housing and resident

organizations (including the cost of

necessary travel for participants in such

training). The funding announced under

this notice is a part of this $10 million.

III. Grant Award

On June 28, 1994, HUD published a

Notice of Funding Availability (NOFA)

for Technical Assistance to Public

Housing Authorities and Public Housing

Police Departments (59 FR 33372)

announcing the availability of up $1.5

million in FY 1994 funds for a 1-year

base period with 4 option years for

comparable amounts based upon an

evaluation of grant performance and the

availability of funds. The Department

reviewed, evaluated and scored the

applications received based on the

criteria in the NOFAs. As a result, HUD

has funded the application announced

below. The announcement of the FY

1994 award, in the amount of

$1,499,348, was published on October

20, 1994 (59 FR 52983). This notice

announces the award of $2,000,000 in

FY 1995 funding to continue activities

for two option years. In accordance with

section 102(a)(4)(C) of the Department of

Housing and Urban Development

Reform Act of 1989 (Pub. L. 101–235,

approved December 15, 1989), the

Department is publishing details

concerning the recipient of this funding

award, as follows:

Grant Recipient: Center for Public

Safety, Inc.

Recipient Contact Person: Thomas J.

Shaughnessy.

Address: Center for Public Safety, Inc.,

Washington Dulles International

Airport, PO Box 20261, Washington,

DC 20041–2261.

Telephone Number: (703) 661–2168.

Original Award Amount: $1,499,348.

Amendment Grant Award Amount:

$2,000,000.

Total Grant Award Amount: $3,499,348.

General Objectives

The United States Department of

Housing and Urban Development (HUD)

and the Center for Public Safety, Inc.,

(grantee) have entered into a grant

agreement for $3,499,348 of Public and

Indian Housing Drug Elimination

Program Technical Assistance funds to:

(1) Develop a program to improve public

housing police departments in

Baltimore HA and Community

Development, Baltimore, MD; Boston

HA, Boston, MA; Buffalo HA, Buffalo,

NY; Cuyahoga Metropolitan HA,

Cleveland, OH; HA of the City of Los

Angeles, Los Angeles, CA; HA of the

City of Oakland, Oakland, CA; HA of the

City of Pittsburgh, Pittsburgh, PA; HA of

the City of Waterbury, Waterbury, CT;

Virgin Islands HA, Virgin Islands;

Philadelphia HA, and Philadelphia, PA,

(2) facilitate law enforcement service

agreements between housing authorities

and local government, and (3) provide

the technical assistance to implement

the program and agreements.

This is a cost-reimbursable grant for

$3,499,348 for a three year base period,

with two optional years. Each additional

fiscal year award will be for comparable

amounts based upon an evaluation of

grant performance and the availability

of funds.

Dated: March 18, 1995.

Joseph Shuldiner,

Assistant Secretary for Public and Indian

Housing.

[FR Doc. 95–11440 Filed 5–9–95; 8:45 am]

BILLING CODE 4210–33–P

DEPARTMENT OF THE INTERIOR

Fish and Wildlife Service

Notice of intent to prepare an

Environmental Impact Statement for

the Proposed Establishment of a

National Wildlife Refuge in

Georgetown, Horry, and Marion

Counties, South Carolina, and Notice

of Meetings to Seek Public

Participation

AGENCY: Fish and Wildlife Service,

Interior.

ACTION: Notice of intent and meetings.

SUMMARY: This notice advises the public

that the U.S. Fish and Wildlife Service,

Southeast Region, intends to prepare an

environmental impact statement (EIS)

for the proposed establishment of a

national wildlife refuge in Georgetown,

Horry, and Marion Counties, South

Carolina, and plans to hold two scoping

meetings in the vicinity of the proposed

refuge to involve the public in the

preparation of the EIS.

DATES: The Service will hold two

scoping meetings as follows: (1) At 7:00

p.m. on June 20, 1995, at the

Georgetown High School Auditorium,

Georgetown, South Carolina; and (2) at